Cargando…
KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
KRAS mutations are among the most commonly occurring mutations in cancer. After being deemed undruggable for decades, KRAS G12C specific inhibitors showed that small molecule inhibitors can be developed against this notorious target. At the same time, there is still no agent that could target KRAS G...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749787/ https://www.ncbi.nlm.nih.gov/pubmed/36531078 http://dx.doi.org/10.3389/fonc.2022.1013902 |